- Monotherapy or combination therapy with metformin, a thiazolidinedione or insulin:
- PO 50mg OD/BD
- Combination therapy with a sulfonylurea:
- PO 50mg OD
- Maximum dose: 100mg/day.
Tablet:
- 50mg
- Taken without regard to food
- Best taken in the morning
Dipeptidyl peptidase-4 (DPP-4) inhibitor
It inhibits the DPP-4 enzyme, which degrades incretin hormones (GLP-1 and GIP). By increasing incretin levels, vildagliptin enhances glucose-dependent insulin secretion and reduces glucagon secretion, leading to better control of blood glucose levels.
- Dizziness
- Headache
- Upper respiratory tract infections
- GI issues (e.g. nausea)
- Excessive sweating
- Low blood sugar levels
- Severe hepatic impairment
- Hypersensitivity to components
- Type 1 DM
- Diabetic ketoacidosis
- ACE inhibitors
- Bendroflumethiazide
- Acetazolamide
- Dexamethasone
- Prednisolone
Drug Status
| Availability | Prescription only |
| Pregnancy | Where benefit outweighs risk |
| Breastfeeding | Not recommended |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Agilis | 50mg | Tablet | 30’s | Biodeal Labs | Biodeal Labs |
| Galvus | 50mg | Tablet | 28’s | Novartis Pharma | Novartis Kenya |
| Glucowell | 50mg | Tablet | 28’s | Cosmos Ltd | Cosmos Ltd |
| Vigliptin | 50mg | Tablet | 30’s | Dawa Ltd | Dawa Ltd |
| Vilda | 50mg | Tablet | 30’s | Innocia Lifesciences | Wessex Pharma |
| Vildagliptin | 50mg | Tablet | 56’s | Novartis Kenya | Novartis Kenya |
| Vilget | 50mg | Tablet | 28’s | Getz Pharma | Surgipharm Ltd |